# OncoC4 Appoints Dr. Dan Janiak as Chief Business Officer

- Link: https://www.thailand-business-news.com/pr-news/oncoc4-appoints-dr-dan-janiak-as-chief-business-officer
- Published: 2026-11-02T19:00:00+07:00
- Author: PR Newswire

|   |

ROCKVILLE, Md., Nov. 2, 2026 /PRNewswire/ — OncoC4, Inc., a late clinical-stage 
biopharmaceutical company developing novel medicines for cancer and immunological
diseases, today announced the appointment of Dr. Dan Janiak as Chief Business Officer.

Dan brings more than 15 years of experience building, financing, and scaling biotechnology
companies across oncology, neurology, and rare diseases. His background spans corporate
strategy, business development, venture investing, and new company formation. Most
recently, he served as Executive Director, Business Development at AstraZeneca, 
where he led oncology platform transactions involving artificial intelligence, machine
learning, and enabling technologies.

"**We are delighted to welcome Dan to OncoC4 at an important stage in the Company’s
growth,**" said Yang Liu, Ph.D., Co-founder, Chief Executive Officer and Chief Scientific
Officer of OncoC4.  "**Dan brings a rare combination of scientific understanding,
strategic judgment and transaction experience across both emerging biotechnology
companies and global biopharmaceutical organizations. His experience building partnerships,
executing complex transactions and developing corporate strategy will be highly 
valuable as we continue to advance our pipeline and pursue opportunities to maximize
the value of our innovative therapies for patients.**"

Prior to joining AstraZeneca, Dan served as President and Chief Operating Officer
of Trotana Therapeutics. Before joining Trotana, Dan was the first employee of Taysha
Gene Therapies, where he served as Senior Vice President of Corporate Strategy and
Business Development and helped build the company from its inception.

Earlier in his career, Dan held strategy and corporate development roles at VelosBio
and AveXis. He began his career in venture investing and new company creation at
Mercury Fund and In-Q-Tel, where he managed investments across therapeutics and 
medical technologies and advised numerous emerging biopharmaceutical companies.

"**OncoC4 has built a compelling portfolio of innovative oncology and immunology
programs, and I am excited to join the company at this important point in its evolution,**"
said Dan Janiak, Ph.D., Chief Business Officer of OncoC4. "**I look forward to working
with Yang and the leadership team to advance OncoC4’s business development and corporate
strategy, build strategic partnerships, and create opportunities that can accelerate
the company’s programs and bring new therapies to patients.**"

Dan is a Kauffman Fellow and earned a Ph.D. from the University of Maryland, College
Park where he held the Fischell Fellowship in Biomedical Engineering.

**About OncoC4**

Headquartered in Rockville, Maryland, OncoC4 is a privately held, late clinical-
stage biopharmaceutical company that is actively engaged in the discovery and development
of novel biologics for the treatment of cancer and immunological diseases, including
neurodegenerative diseases. OncoC4’s pipeline features assets with first-in-class
and best-in-class potential targeting both novel and well-validated targets across
oncology and immunological diseases. Among them, cesalatamig is a wholly owned and
highly differentiated PD-1/VEGF bispecific antibody currently undergoing rapid global
clinical development in multiple oncology indications. Tasafustobart (ONC-841) is
a first-in-class anti-SIGLEC-10 antibody currently in a Phase 2 trial for oncology
indications and a Phase 1 trial for neurodegenerative diseases. In addition, OncoC4
recently initiated a first-in-human trial of ONC-783, a first-in-class T cell engager
targeting a novel CD24 epitope selectively expressed across a broad spectrum of 
human cancers, including solid tumors and hematological malignancies, in the United
States. OncoC4 has a strategic collaboration with BioNTech to co-develop gotistobart(
BNT316/ONC-392), a tumor microenvironment-selective Treg depletion candidate targeting
CTLA-4, in multiple solid tumor indications, including an ongoing pivotal clinical
trial in squamous non-small cell lung cancer.

For more information, please visit [www.oncoc4.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4811627-1&h=3860568455&u=http%3A%2F%2Fwww.oncoc4.com%2F&a=www.oncoc4.com)

**Contacts**

Media Relations
[media@oncoc4.com](https://www.thailand-business-news.com/pr-news/media@oncoc4.com)

Investor Relations
[ir@oncoc4.com](https://www.thailand-business-news.com/pr-news/ir@oncoc4.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [OncoC4 Appoints Dr. Dan Janiak as Chief Business Officer ](http://www.prnasia.com/story/archive/5086349_AE86349_0?rand=184833)